JP5331962B2 - 炎症性疾患のための薬草組成物 - Google Patents

炎症性疾患のための薬草組成物 Download PDF

Info

Publication number
JP5331962B2
JP5331962B2 JP2008532961A JP2008532961A JP5331962B2 JP 5331962 B2 JP5331962 B2 JP 5331962B2 JP 2008532961 A JP2008532961 A JP 2008532961A JP 2008532961 A JP2008532961 A JP 2008532961A JP 5331962 B2 JP5331962 B2 JP 5331962B2
Authority
JP
Japan
Prior art keywords
composition
inflammatory
extract
compound
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008532961A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510051A (ja
JP2009510051A5 (cg-RX-API-DMAC7.html
Inventor
ビジャイ・チャウハン
アシシュ・スター
ダナンジャイ・サプレ
スワティ・バル−テンベ
アショク・クマール・ガンゴパディヤイ
アシャ・クルカルニ−アルメイダ
サプナ・ハシト・パリク
Original Assignee
ピラマル エンタープライジーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピラマル エンタープライジーズ リミテッド filed Critical ピラマル エンタープライジーズ リミテッド
Publication of JP2009510051A publication Critical patent/JP2009510051A/ja
Publication of JP2009510051A5 publication Critical patent/JP2009510051A5/ja
Application granted granted Critical
Publication of JP5331962B2 publication Critical patent/JP5331962B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
JP2008532961A 2005-09-30 2006-09-28 炎症性疾患のための薬草組成物 Expired - Fee Related JP5331962B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN1226MU2005 2005-09-30
IN1226/MUM/2005 2005-09-30
US73644305P 2005-11-14 2005-11-14
US60/736,443 2005-11-14
PCT/IB2006/053540 WO2007036900A2 (en) 2005-09-30 2006-09-28 Herbal composition for inflammatory disorders

Publications (3)

Publication Number Publication Date
JP2009510051A JP2009510051A (ja) 2009-03-12
JP2009510051A5 JP2009510051A5 (cg-RX-API-DMAC7.html) 2009-10-01
JP5331962B2 true JP5331962B2 (ja) 2013-10-30

Family

ID=37900158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008532961A Expired - Fee Related JP5331962B2 (ja) 2005-09-30 2006-09-28 炎症性疾患のための薬草組成物

Country Status (10)

Country Link
US (2) US7635494B2 (cg-RX-API-DMAC7.html)
EP (1) EP1931366B1 (cg-RX-API-DMAC7.html)
JP (1) JP5331962B2 (cg-RX-API-DMAC7.html)
AU (1) AU2006296197B2 (cg-RX-API-DMAC7.html)
CA (1) CA2624049C (cg-RX-API-DMAC7.html)
EA (1) EA014070B1 (cg-RX-API-DMAC7.html)
GE (1) GEP20115332B (cg-RX-API-DMAC7.html)
MA (1) MA29890B1 (cg-RX-API-DMAC7.html)
PL (1) PL1931366T3 (cg-RX-API-DMAC7.html)
WO (1) WO2007036900A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981131B2 (en) * 2007-07-27 2015-03-17 Piramal Enterprises Limited Tricyclic compounds for the treatment of inflammatory disorders
WO2009084032A2 (en) * 2007-12-03 2009-07-09 Vedic Elements Private Limited Stable hydrophobic topical herbal formulation
WO2012014216A1 (en) * 2010-07-28 2012-02-02 Laila Nutraceuticals 7-hydroxyfrullanolide and its analogs for prevention, control and treatment of metabolic disorders
US10105347B2 (en) 2009-02-02 2018-10-23 Laila Nutraceuticals Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels
CN102292093B (zh) * 2009-02-02 2015-01-28 莱拉营养食品有限公司 用于代谢综合症控制的选自绒毛戴星草和莽吉柿的混合物
WO2011033524A2 (en) * 2009-08-04 2011-03-24 Laila Nutraceuticals Agents from ficus hispida for the amelioration of metabolic syndrome and related diseases
WO2011083397A1 (en) * 2010-01-05 2011-07-14 Himalaya Global Holdings Limited Herbal composition for skin disorders
PH12013500451A1 (en) * 2010-09-11 2013-05-20 Laila Nutraceuticals Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels
US8263579B2 (en) * 2011-01-24 2012-09-11 Piramal Healthcare Limited Anti-inflammatory compounds
TW201427677A (zh) * 2012-10-23 2014-07-16 Piramal Entpr Ltd 用於預防及治療腫瘤壞死因子-α媒介疾病中藥組合物
EP3313384A4 (en) 2015-06-23 2019-04-03 Nobilis Therapeutics, Inc. THERAPEUTIC IMMUNE MODULATION USING NOBLE GAS COMPOSITIONS
WO2017203540A1 (en) * 2016-05-21 2017-11-30 Laila Impex Dietary supplements and compositions for enhancing physical performance and energy levels

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646687A (en) * 1994-12-29 1997-07-08 Lucent Technologies Inc. Temporally-pipelined predictive encoder/decoder circuit and method
US6204523B1 (en) * 1998-11-06 2001-03-20 Lumileds Lighting, U.S., Llc High stability optical encapsulation and packaging for light-emitting diodes in the green, blue, and near UV range
US6686676B2 (en) * 2001-04-30 2004-02-03 General Electric Company UV reflectors and UV-based light sources having reduced UV radiation leakage incorporating the same
US6989412B2 (en) * 2001-06-06 2006-01-24 Henkel Corporation Epoxy molding compounds containing phosphor and process for preparing such compositions
US6841647B2 (en) * 2001-11-06 2005-01-11 National Starch And Chemical Investment Holding Corporation Fluid resistant silicone encapsulant
US7160972B2 (en) * 2003-02-19 2007-01-09 Nusil Technology Llc Optically clear high temperature resistant silicone polymers of high refractive index
US7261441B2 (en) * 2004-02-27 2007-08-28 Avago Technologies Ecbu Ip (Singapore) Pte. Ltd. LED device and method for directing LED light
WO2006016228A2 (en) * 2004-08-02 2006-02-16 Prashanth Kumar V Cytotoxic peptide alkaloid and pharmaceutical compositions for the treatment of neoplastic diseases
US7229934B2 (en) * 2004-10-18 2007-06-12 International Business Machines Corporation Porous organosilicates with improved mechanical properties

Also Published As

Publication number Publication date
CA2624049A1 (en) 2007-04-05
WO2007036900A2 (en) 2007-04-05
HK1112418A1 (en) 2008-09-05
CA2624049C (en) 2016-01-12
AU2006296197A2 (en) 2008-06-05
MA29890B1 (fr) 2008-10-03
AU2006296197A1 (en) 2007-04-05
US7635494B2 (en) 2009-12-22
US20090269427A1 (en) 2009-10-29
JP2009510051A (ja) 2009-03-12
EA200800850A1 (ru) 2008-10-30
US20080254157A1 (en) 2008-10-16
AU2006296197B2 (en) 2012-08-09
PL1931366T3 (pl) 2013-11-29
US8206756B2 (en) 2012-06-26
GEP20115332B (en) 2011-11-25
WO2007036900A3 (en) 2007-08-02
EP1931366B1 (en) 2013-05-29
EA014070B1 (ru) 2010-08-30
EP1931366A2 (en) 2008-06-18

Similar Documents

Publication Publication Date Title
US7635494B2 (en) Herbal composition for inflammatory disorders
US20070032544A1 (en) Medicinal acidic cannabinoids
KR101285234B1 (ko) 백미 추출물을 포함하는 관절염 예방 및 치료용 조성물
JP5478486B2 (ja) 植物抽出物及びその治療的使用
Hanh et al. Toxicity and anti-inflammatory activities of an extract of the Eleutherine bulbosa rhizome on collagen antibody-induced arthritis in a mouse model
US20100120902A1 (en) Standarized bioactive herbal extracts
Cahyo et al. Anti-Inflammatory and analgesic potential of Chromolaena odorata: A review
CN101304756B (zh) 用于炎性病症的草药组合物
JP2000503686A (ja) 黄栢皮とオミナエシ植物の混合抽出物を含有するc型肝炎治療用製薬組成物
TWI320714B (en) Plant extracts for the treatment of rheumatoid arthritis
KR20190060331A (ko) 데히드로코스투스락톤을 유효성분으로 포함하는 염증성 장질환의 예방 또는 치료용 조성물
US6413553B1 (en) Herbal formulation of a combination of Piper betel and Murrya koenigii extracts for blocking 5 lipoxygenase activity
US7862837B2 (en) Herbal composition
Maghsoudi et al. Antiinflammatory Effect of Alcoholic Extract of Nigella sativa L on Bovine Fibroblast-like synoviocyte and THP-1
Mahmoud et al. Prevention of tri-nitrobenzene of sulfonic acid-induced colitis in chicken by using extract of Aloe vera.
MX2008004291A (es) Composicion herbaria para trastornos inflamatorios
HK1112418B (en) Herbal composition for inflammatory disorders
Gopalakrishnan et al. Antihepatotoxic acticity of Coccinia indica
CN114601828B (zh) 一种雪灵芝提取物及其在制备抗炎药物中的用途
Nahar et al. Anti-inflammatory Effect of Methanolic Extract of Mangifera Indica Leaves on Inflammed Rats in Comparison to Indomethacin
WO2023037299A1 (en) Anti-inflammatory compositions comprising ginger and turmeric
CN102210680A (zh) 一种青藤碱衍生物通过阻断巨噬细胞p38 MAPK信号通路治疗炎症疾病
CN121588097A (zh) 用于治疗类风湿性关节炎的组合物
Henri et al. Effects of Cola anomala (K. Schum.) water/ethanol pods extract on the inflammation and intestinal secretion in lipopolysaccharide-induced diarrhea.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090814

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120820

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130305

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130314

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130521

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130619

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130619

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees